CA1067407A - Pharmaceutical preparation in the form of a foil having an active substance incorporated therein - Google Patents
Pharmaceutical preparation in the form of a foil having an active substance incorporated thereinInfo
- Publication number
- CA1067407A CA1067407A CA230,802A CA230802A CA1067407A CA 1067407 A CA1067407 A CA 1067407A CA 230802 A CA230802 A CA 230802A CA 1067407 A CA1067407 A CA 1067407A
- Authority
- CA
- Canada
- Prior art keywords
- cellulose
- foil
- composition according
- sheet
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000011888 foil Substances 0.000 title abstract description 98
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title description 41
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 229920002678 cellulose Polymers 0.000 claims abstract description 42
- 239000001913 cellulose Substances 0.000 claims abstract description 42
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 29
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 29
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims abstract description 29
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 8
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims abstract description 8
- 239000000262 estrogen Substances 0.000 claims abstract description 6
- 239000000583 progesterone congener Substances 0.000 claims abstract description 5
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 4
- 239000001923 methylcellulose Substances 0.000 claims abstract description 4
- 235000010981 methylcellulose Nutrition 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims description 30
- 239000000725 suspension Substances 0.000 claims description 27
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- -1 hydroxyalkyl ether Chemical compound 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 229920002675 Polyoxyl Polymers 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 239000012456 homogeneous solution Substances 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 7
- 229960002900 methylcellulose Drugs 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 239000001856 Ethyl cellulose Substances 0.000 abstract description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- HLKZFSVWBQSKKH-UHFFFAOYSA-N but-3-enoic acid;1-ethenylpyrrolidin-2-one Chemical compound OC(=O)CC=C.C=CN1CCCC1=O HLKZFSVWBQSKKH-UHFFFAOYSA-N 0.000 abstract description 2
- 235000019325 ethyl cellulose Nutrition 0.000 abstract description 2
- 229920001249 ethyl cellulose Polymers 0.000 abstract description 2
- 229960004667 ethyl cellulose Drugs 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical group COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 abstract description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 35
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 25
- 229960002568 ethinylestradiol Drugs 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 23
- 229960004400 levonorgestrel Drugs 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 6
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 6
- 229960001652 norethindrone acetate Drugs 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 229940081974 saccharin Drugs 0.000 description 4
- 235000019204 saccharin Nutrition 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000009470 Theobroma cacao Nutrition 0.000 description 3
- 235000002864 food coloring agent Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- XZBJVIQXJHGUBE-HZMVJJPJSA-N fluocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O XZBJVIQXJHGUBE-HZMVJJPJSA-N 0.000 description 2
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 2
- 229960003236 glisoxepide Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 239000003232 water-soluble binding agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KLCDQSGLLRINHY-UHFFFAOYSA-N 1-phenyldiazenylnaphthalen-2-amine Chemical compound NC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1 KLCDQSGLLRINHY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000011797 cavity material Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A pharmaceutical preparation for internal or external use includes a foil incorporating one or more pharmacologically active ingredients, the material forming the foil being soluble in water or organic solvents. The foil forming material may be poly-N-vinyl-pyrrolidone, vinylpyrrolidone-vinyl acetate, methyl- and ethyl-cellulose, hydroxypropyl-cellulose, hydroxyethyl-cellulose or methylhydroxypropyl-cellulose. The active ingredient may be a gestagen, oestrogen, mixture of a gestagen and an oestrogen, a tranquillizer, an anti-diabetic, sulphonamide, antibiotic, a trichomonal agent or an inflammation inhibitor.
A pharmaceutical preparation for internal or external use includes a foil incorporating one or more pharmacologically active ingredients, the material forming the foil being soluble in water or organic solvents. The foil forming material may be poly-N-vinyl-pyrrolidone, vinylpyrrolidone-vinyl acetate, methyl- and ethyl-cellulose, hydroxypropyl-cellulose, hydroxyethyl-cellulose or methylhydroxypropyl-cellulose. The active ingredient may be a gestagen, oestrogen, mixture of a gestagen and an oestrogen, a tranquillizer, an anti-diabetic, sulphonamide, antibiotic, a trichomonal agent or an inflammation inhibitor.
Description
o~
This invention relates to a pharmaceutical prepaxation in the form of a foil having an active substance incorporated the~ein, for internal and external use.
Belgian Patent No. 637,363 describes paper foils coated with active substances suitabLe for oral use. The foils consist of cellulose fibres insoluble in water and a water-soluble binding agent. The water-soluble binding agent i9 preferably sodium carb-oxymethyl-cellulose. The active substance may be applied to the paper foil by dropping a solution of the active substance onto the foil, by spreading the solid active substance on the foil or by drawing the foil through a solution of the active substance.
The discontinuous process of separately making the foil and apply-ing the active substance has the disadvantage that the accuracy of the dosage is not very good which is of great importance because acti~e substances are generally used in small doses at the present time. Inaccuracies arise not only in applying the active substance, but also in the manufacture and pretreatment of the foil and because of variations during storage of the foil material. Thus, for example, it has been found that in using foil drawing machines as prescribed in Belgian Patent No. 637,363, non-uniform layers of foil are formed, and that the foil shrinks during drying.
However, it is easy to understand that with non-uniform ma~erial the take-up of active substance is also not uniform. Moreover, an active substance bound only on the surface can be partially removed during handling of the foils, for example, during packing.
The sodium carboxymethyl-ceIlulose used as binding agent becomes detached in the stomach and there is liberated carbo~ymethyl-cellulose, which includes some of the active substance and liber-ates it only slowly or not at all.
The present invention is based on the observation that foils having a constant thickness and a uniform distribution of active substance can be obtained by making foils having the active - 1 - ~
~7 substance inco~porated therein and using foil formers that are soluble in water or or~anic solvents.
The present invention provides a pharmaceut~cal preparation in the form of a foil, wherein the foil incorporates one or more pharmacologicall~ active ingredi.en-ts and is obtained from a foil forming material or materials soluble in water or organic sol~ents. Especially suitable are foil forming materials soluble both in water and organic solYents.
Suitable foil formers there include poly-N-vinyl-pyrrolidone, vinylpyrrolidone-vinyl acetate, methyl- and ethyl-cellulose, but preferably non-ionic water-soluble hydroxyalkyl ethers of cellulose such as, ~or example, hydroxypropyl-cellulose, hydroxyethyl-cellulose and methylhydroxypropyl-cellulose.
In addition to the active substance or substances, the foil may contain fillers and advantageously a small amount of a release agent.
Suitable release agents are, polyoxyethylene-polyoxy-propylene polymer (PLURaNIC F 68 ~?, polyoxyl stearates, alkyl-or acyl-substituted polyaddition product~ of ethylene oxide, for example, CR~MOPHOR EL ~ , silicones and silicone parting emulsions, glycerine, propylene glycol and metal soaps.
The fillers include cellulose, sugars, for example, lactose, dextrose and cane sugar, starches, polyhydric alc.ohols, for example, m-nnitol, calcium carbonate, calcium phosphate, talcum and dyestuffs in soluble form or as pigments. When soluble fillers and soluble active substances are used, a transparent smooth foil is formed, and when insoluble flllers or insoluble active substances are used a white or coloured paper-like foil is formed.
A11 acti~e substances used in human and veterinary medicine can be used in accordance with the invention. ~or internal use there comes into consideration especially oral administration. As external use there is to be understood, more especially, topical administration on the sk:in and in body cavi-ties such, for example, as the nose, ears and vagina. The active substances may be, for example, gestayens, oestrogens, mixtures of gestagens and oestrogens, tranqui:llizers, anti.-diabetics, sulphonamides, antibioticsl trichomonal agents and inflammation inhibitors, for example,: corticoids.
The medicaments may be present in the car~ier materials in a dissol~ed or uniformly .suspended state. The proportion of acti.ve substance in the foil may be from 0 to 60 per cent. The suraces may be cut or perforated to form single doses (units), which contain quantities o~ active substance such as are usually present in tablets, dragées, salves and suppositories. Thus, the quantity of active substance per single dose may be as high as desired depending on the mode of; use and between about 1 ~g and 0.5 g, and the lower and upper dose may easily be smaller or greater. It is, of course, possible also to make carriers free from active substance (placebos).
For the production of the medicinal preparations in foil form of the invention the active substance and/or parting compound is disso.lved or suspended, the foil former and optionally the filler is introduced, optionally homogenized, and the solution or suspension is drawn out on a foil drawing machine to a sheet.
The foil obtained by drying the sheet is divided into sections (units).
Into the solution or suspension are introduced the foil former in a proportion by weight of about 6 to 7.0 per cent, the filler in a proportion by weight of up to 30 per cent and the release agent preferably in a proportion by weight of 0.01 to per cent are introduced into the solution or suspension.
The content of solvent or suspension medium is about ~8 to 8~ per cent by weight and consists of water and/or one or 1~i7~0~
moxe organic solvents. The organic solvents are physiologically tolerable solvents or solvents that are removed except for a physiologically unobjectionable residue. ~uch solvents axe, for example, ethyl alcohol, isopropanol and methylene chIoride, and mixtures thereof. Water and ethyl alcohol or mixtures of water and ethyl alcohol are preferably used.
The layer thickness of the wet sheet is about 0.1 to
This invention relates to a pharmaceutical prepaxation in the form of a foil having an active substance incorporated the~ein, for internal and external use.
Belgian Patent No. 637,363 describes paper foils coated with active substances suitabLe for oral use. The foils consist of cellulose fibres insoluble in water and a water-soluble binding agent. The water-soluble binding agent i9 preferably sodium carb-oxymethyl-cellulose. The active substance may be applied to the paper foil by dropping a solution of the active substance onto the foil, by spreading the solid active substance on the foil or by drawing the foil through a solution of the active substance.
The discontinuous process of separately making the foil and apply-ing the active substance has the disadvantage that the accuracy of the dosage is not very good which is of great importance because acti~e substances are generally used in small doses at the present time. Inaccuracies arise not only in applying the active substance, but also in the manufacture and pretreatment of the foil and because of variations during storage of the foil material. Thus, for example, it has been found that in using foil drawing machines as prescribed in Belgian Patent No. 637,363, non-uniform layers of foil are formed, and that the foil shrinks during drying.
However, it is easy to understand that with non-uniform ma~erial the take-up of active substance is also not uniform. Moreover, an active substance bound only on the surface can be partially removed during handling of the foils, for example, during packing.
The sodium carboxymethyl-ceIlulose used as binding agent becomes detached in the stomach and there is liberated carbo~ymethyl-cellulose, which includes some of the active substance and liber-ates it only slowly or not at all.
The present invention is based on the observation that foils having a constant thickness and a uniform distribution of active substance can be obtained by making foils having the active - 1 - ~
~7 substance inco~porated therein and using foil formers that are soluble in water or or~anic solvents.
The present invention provides a pharmaceut~cal preparation in the form of a foil, wherein the foil incorporates one or more pharmacologicall~ active ingredi.en-ts and is obtained from a foil forming material or materials soluble in water or organic sol~ents. Especially suitable are foil forming materials soluble both in water and organic solYents.
Suitable foil formers there include poly-N-vinyl-pyrrolidone, vinylpyrrolidone-vinyl acetate, methyl- and ethyl-cellulose, but preferably non-ionic water-soluble hydroxyalkyl ethers of cellulose such as, ~or example, hydroxypropyl-cellulose, hydroxyethyl-cellulose and methylhydroxypropyl-cellulose.
In addition to the active substance or substances, the foil may contain fillers and advantageously a small amount of a release agent.
Suitable release agents are, polyoxyethylene-polyoxy-propylene polymer (PLURaNIC F 68 ~?, polyoxyl stearates, alkyl-or acyl-substituted polyaddition product~ of ethylene oxide, for example, CR~MOPHOR EL ~ , silicones and silicone parting emulsions, glycerine, propylene glycol and metal soaps.
The fillers include cellulose, sugars, for example, lactose, dextrose and cane sugar, starches, polyhydric alc.ohols, for example, m-nnitol, calcium carbonate, calcium phosphate, talcum and dyestuffs in soluble form or as pigments. When soluble fillers and soluble active substances are used, a transparent smooth foil is formed, and when insoluble flllers or insoluble active substances are used a white or coloured paper-like foil is formed.
A11 acti~e substances used in human and veterinary medicine can be used in accordance with the invention. ~or internal use there comes into consideration especially oral administration. As external use there is to be understood, more especially, topical administration on the sk:in and in body cavi-ties such, for example, as the nose, ears and vagina. The active substances may be, for example, gestayens, oestrogens, mixtures of gestagens and oestrogens, tranqui:llizers, anti.-diabetics, sulphonamides, antibioticsl trichomonal agents and inflammation inhibitors, for example,: corticoids.
The medicaments may be present in the car~ier materials in a dissol~ed or uniformly .suspended state. The proportion of acti.ve substance in the foil may be from 0 to 60 per cent. The suraces may be cut or perforated to form single doses (units), which contain quantities o~ active substance such as are usually present in tablets, dragées, salves and suppositories. Thus, the quantity of active substance per single dose may be as high as desired depending on the mode of; use and between about 1 ~g and 0.5 g, and the lower and upper dose may easily be smaller or greater. It is, of course, possible also to make carriers free from active substance (placebos).
For the production of the medicinal preparations in foil form of the invention the active substance and/or parting compound is disso.lved or suspended, the foil former and optionally the filler is introduced, optionally homogenized, and the solution or suspension is drawn out on a foil drawing machine to a sheet.
The foil obtained by drying the sheet is divided into sections (units).
Into the solution or suspension are introduced the foil former in a proportion by weight of about 6 to 7.0 per cent, the filler in a proportion by weight of up to 30 per cent and the release agent preferably in a proportion by weight of 0.01 to per cent are introduced into the solution or suspension.
The content of solvent or suspension medium is about ~8 to 8~ per cent by weight and consists of water and/or one or 1~i7~0~
moxe organic solvents. The organic solvents are physiologically tolerable solvents or solvents that are removed except for a physiologically unobjectionable residue. ~uch solvents axe, for example, ethyl alcohol, isopropanol and methylene chIoride, and mixtures thereof. Water and ethyl alcohol or mixtures of water and ethyl alcohol are preferably used.
The layer thickness of the wet sheet is about 0.1 to
2 mm and that of the dry foil is about 0.05 to 1 mm, and prefer-ably 0.07 to 0.3 mm.
The process of making the medicinal preparation in foil form in one operation (a continuous process) has the advantage that the active substance is homogeneously and uniformly distri-buted in the medicament carrier. By varying the concentration of the~active substance in the carrier, the thickness of the foil and the area of the foil the unit dose can be varied in a very simple manner.
Foils can also be made with a sheet in which different active substances and/or varying concentrations of active substance are incorpoxated side by side over the width of the web of foil.
Zo ` By means of a special doctor, which consists of two or more compartments, different solutions or suspensions can be drawn out without mixing to form a coherent sheet. The width and thickness of the sheet is separateIy adjustable for each compartment. If desired, zones (strips) having different active substances or different concentrations are made visible by different dyestuffs.
By drying the wet sheet there is obtained a foil, which by being divided in an appropriate manner, for example, by perforation, yields units containing different active substances and/or concentrations of active substance or units containing no active substance. Foils containing different active substances and/or different concentrations of active substance are required for making multi-phase preparations, for example, for making ~L~7~(37 contraceptive preparations~ The possibility o;E the spatial separation of active substances that are incompatible with one another i~ one foil unit improves the stability oE the individ-ual active substances. ~oils for intravaginal application may, for example, also be rolled round an ordinary commercial tampon.
The following examples illustrate the invention; with the exception of Examples 5 and 16, the preparations described in the examples are primarily suitable for oral administration.
Example 1 Preparation for 1000 units:
0.25 g of d-norgestrel, 0.05 g of ethinyl-oestradiol and 0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 95.00 g of ethyl alcohol while stirring, and into this is introduced a powdered mixture of 16.93 g of hydroxypropyl-ceIlulose and 16.93 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The composition of one unit:
0.25 mg of d-norgestrel 0.05 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.93 mg of hydroxypropyl-cellulose 16.93 mg of cellulose _. .
35.00 mg One unit corresponds to an area of about 3 cm2.
~ppearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
~0~7~
Exam~le 2 A preparation for 1000 units:
1.10 g of Cremophor EL ~ are dissol~ed in 152.00 g of water. In this solution are suspended 0.25 g of micronized d-norgestrel and 0.05 g of micronized ethinyl-oestradiol and if necessary homogenizea. Into the suspension are introduced 22.10 g of hydroxypropyl-ceIlulose and 16.50 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The com,position for one unit:
0.25 mg of d-norgestrel 0.05 mg of ethinyl-oestradiol 1.10 mg of Cremophor EL ~
22.10 mg of hydroxypropyl-cellulose 16.50 mg of cellulose 40.00 mg One unit corresponds to an area of about 3 cm .
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
'Ex'ample 3 A preparation for 1000 units:
0.03 ~ of d-norgestrel and 0.84 g of polyoxyl-40-stearate are dissolved, while stirring, in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 ~ of hydroxypropyl-ceIlulose and 17.20 g of cellulose.
~ ~7~q The suspension thus obtained .is drawn on a sultable ~oil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried~
The composition of one.unit:
0.03 mg o~ d-norgestrel 0.84 mg of polyoxyl-40-stearate 16.93 mg of hydroxypropyl-ceIlulose 17.20 mg of cell.ulose ..35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: ~hi.tel paper-like.
The dry foil has a thickness of about 170 ~m.
Example 4 A preparation for 1000 units:
1.10 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 152.00 g of demineralized water. In this solution is suspended 0.03 g of microized d-norgestrel, and if necessary homogenized. Into the suspension are introduced.
22..10 g of hydroxypropyl-cellulose and 16.77 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of.500 ~m, and is then dried.
The composition for one unit:
0O03 mg of d-norgestrel 1.10 mg of polyoxyethylene-polyoxypropylene polymer 22.10 mg of hydroxypropyl-cellulose 16.77 mg of cellulose -40.00 mg One unit corxesponds to an area of about 3 cm2.
Appearance of the.foil: white, paper-like.
The dry foil has a thickness of about 170 ~m, Exam_le.5 A preparation for 1000..units 0~025 g of fluocortolone trimethylacetate and 0.183 ~ of gylcerine are dissolved in .30.000 g of ethy.l alcohol. Into this solution are introduced 7.292 g of hydroxypropyl-cellulose~
The solution thus obtained is draw on a suitable foil drawing apparatus to a sheet having a thickness to.500 ~m, and is then dried.
The composition of one unit:
0.025 mg fluocortolone trimethylacetate 0..183 mg of glycerine - 7:.292 mg of hydroxypropyl-cellulose 7.500 mg One unit corresponds to an area of about 1 cm2.
Appearance of the foil: transparent.
The dry foil has a thickness of about 70 ~m.
The foil is suitable for topical use.
Examp:le 6 A preparation for 1000 units:
10.00 g of 7-chloro,2-methylamino-5-phenyl-3~-1,4-benzo-diazepine-4-oxide and 0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 g of hydroxypropyl-cellulose and 7.23 g of cellulose.
~6'74t~~
The suspension thus o~tained is drawn on a suitable foil dra~ing appaxatus to a sheet having a thickness o~ 500 ~m, and is then dried.
The composition of one unit:
10.00 mg of 7-chloro-2-meth~lamino-5-phenyl-3H-1,4-benzo-diazepine-~-oxide 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.93 mg of hydroxypropyl-cellulose 7.23 mg of cellulose 35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: yello~, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 7 A preparation for 1000 units:
1.00 g of norethisterone acetate, 0.03 g of ethinyl-oestradiol and 0.84 g of polyoxyethylene-polyoxypropylene polymer and dissolved in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 g of hydroxypropyl-cellulose and 16.20 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The composition for one unit:
1.00 mg of norethisterone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.93 mg of hydroxypropyl-cellulose 16.20 mg of cellulose 35.00 mg 4~
One unit corresponds to an area of about 3 cm2.
~ppearance of the ~oil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 8 A preparation for 1000units:
1.00 g of norethisterone acetate 0.03 g of ethinyl-oestradiol and 0.84 g of propylene glycol are dissolved in~.a mixture of 101.60 g of methylene chloride and 26.40 g of ethyl alcohol, Into this so}ution is introduced a powdered mixture of 8.47 g of hydroxypropyl-ceIlulose, 8.47 g of hydroxyethyl-ceIlulose and 16.19 g of cellulose.
The suspension thus obtained is drawn on a suitable fo'il drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The composition fox one unit:
1.00 mg of norethistèrone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of propylene glycol 8.47 mg of hydroxypropyl-cellulose 8.47 mg of hydroxyethyl-cellulose 16.19 mg of cellulose 35.00 ~g One unit corresponds to an area of about 3 cm2O
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 9 A preparation for 1000 units:
1.00 g of norethisterone aceta-te, 0.03 g of ethinyl-oestradiol and 7~
0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 101.60 g of methylene chloride and 25.40 ~ of ethyl alcohol. Into this solution is introduced a powdered mixture o~
16~93 g o:E hydroxyethyl-cellulose and 16.20 g of starch.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a~hickness of 500 ~m, and is then dried.
The composition for one unit:
1.00 mg o norethisterone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 15.93 mg of hydroxyethyl-cellulose and 16.20 mg of starch 35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 10 A preparation for 1000 units:
1.00 g of norethisterone acetate 0.03 g of ethinyl-oestradiol and 0.84 g of polyoxyl-40-stearate are dissol~ed in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 g of hydroxypropyl-cellulose 8.10 g of lactose and 8.10 g of maize starch.
The suspension thus obtained is drawn on a suitable ~ ~ t7~ ~ ~
foil drawing apparatus to a sheet ha~ing a thickness of 500 ~m, and is then dried.
The composition ~or one unit:
1.00 mg of norethisterone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyl-40-stearate 16.93 mg of hydroxypropyl-cellulose 8.10 mg of lactose 8.10 mg of maize starch 35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: ~hite, paper-like.
The dry foil has a thickness of about 170 ~m.
Example ll A preparation for 1000 units:
1.00 g of norethisterone~(l7~-ethinyl-19-nor-testosterone) 0.03 g of ethinyl-oestradiol and 0.22 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 84.75 g of ethyl alcohol and 4.00 g of water. Into this solution is introduced a powdered mixture of 16.00 g of hydroxypropyl-cellulose and 16.00 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 600 ~m and then dried.
The composition for one unit:
1.00 mg of noxethisterone ~17~-ethinyl-l9-nor-testosterone) 0.03 mg o~ ethinyl-oestradiol 0.22 mg of polyoxyethylene-polyoxypropylene polymer 16.00 mg of hydroxypropyl-cellulose ~7~
16.00 mg of cellulose .
33.25 mg One unit corresponds to an area of about 3 çm2.
Appear~nce o~ the ~oil: white, paper~like.
The dry foil has a thickness of approx. 230 ~m.
Example 12 A preparation for 1000 uni*s:
4.0 g of glisoxepide.* in micronised form are suspended in 0..9 g of polyoxyl-40-stearate dissolved in .152.0 g of water, and:if necessary homogenized. Into the suspension are introduced 15.0 g of hydxoxyethyl-ceIlulose and 15.1 g of calcium carbonate.
The suspension thus obtained is drawn on a suitable foil drawing appara*us to a sheet having a thickness of.500 ~m and dried.
The composition for one unit:
4.00 mg of glisoxepide.*
0090 mg of polyoxyl-40 stearate 15.00 mg of hydroxyethyl-cellulose 15.10 mg of calc.ium carbonate -.35.00 mg One unit corresponds.to an area of about 3 cm2.
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
4-{~-[~-(5-methyl-isoxazol-3-carboxamido~-ethyl~-benzolsulphonyl}-l,l-hexamethylene-semicarbazide.
Example 13 A preparation for lOOO.units:
0.030 g of d norgestreI are dissolved in 40.000 g of methylene chloride and 55.000 g of ethanol. Into this solution are introduced 0.840 g of silicone oil 6.930 g of methyl-cellulo:se and 10.000 g of poly-N.-vinyl-pyrrolidone and 17.200 g of starch~,and i~ necessary homoyenlzed.
The suspension thus obta:ined is drawn on a :suitable foil drawing apparatus to a sheet having a t:hickness of;500 ~m and dried.
The composition of one~.unit:
Ø.030 mg of d-norgestrel 0.840 mg of silicone oil 6.930 mg of methyl-cellulose 10.000 mg of poly-N-~inyl-pyrrolidone 17:.200 mg of starch .35.000 mg One unit corresponds to an area of about.3 cm .
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Ex'ampl'e''14 A preparation for 1000. units:
0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 95.00 g of ethyl alcohol while stirring, and into this solution is introduced a powdered mixture of 17.08 g of hydroxypropyl-ceIlulose and 17.08 g of cellulose.
The suspension thus obtained is drawn on a suitahle foil dra~ing app~ratus to a sheet having a thickness of 500 ~m and then dried~
~)t;i7~0P7 The compositi.on ~or one unit:
0.84 mg of polyoxyethylene-polyoxypropylene polymer 17.08 mg of hydroxypropyI-ceIlulsoe 17.08 mg of cellulose ..35.00 mg Exampl:e :15`
A preparati.on for 1000 units:
0.04 g of saccharin 0.04 g of cream essence and 0.40 g of polyoxyethylene-polyoxypropyl.ene:polymer are dissolved in a mixture of 79.00 g of ethyl alcohol and 4.00 g of water. Into this solution are introduced .30:.00 g of iron (II? .umarate, .15.00 g of hydroxypropyl-cellulose, 5..52 g of cocoa and 4:.00 g of ceI.lulose, and if necessaxy homogenized.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 0.5 mm, and then dried.
The composition for one unit:
30.00 mg of iron (II) :fumarate 15.00 mg of hydroxypropyl-cellulose 4.00 mg of cellulose 0.40 mg of polyoxyethylene-polyoxypropylene polymer 5..52 mg of co.coa 0.04 mg of saccharin 0.04 mg of cream ess~ence 55.00 mg. Weight per unit.
One unit corresponds to an ar~a of about 3 cm2.
Appearance o the foil: pale red-brown.
~;7~
Example 16 Foils for intravaginal application;
The foil is prepared in accordance with Example ll.
The co~position of one unit 100.0 mg of S-morpholinomethyl-3-(5-nitro-1-methyl-2-imidazolyl)-methyleneamino-2-oxazoli-done.HCl 8.4 mg of Cremopho~ EL ~
169.2 mg of methylhydroxypropyl-cellulose 72.4 mg of cellulose 350.0 mg. Weight of one unit.
One unit corresponds to an area of about 8 x 4 cm.
Appearance of the foil: pale yellow.
The $oil (1 unit~ is either rolled round an ordinary commercial tampon or is itself rolled to form a naErow tube.
EXample 17 A two phase preparation Part 1: 21 units containing active substance.
Part 2: 7 units without active substance.
A preparation for 3000 units. Part 1.
0.75 g of d-norgestrel 0.15 g of ethinyl-oestradiol and 0.54 g of polyoxethylene-polyoxypropylene polymer are dissol~ed in a mixture of 237.00 g of ethyl alcohol and 12.00 g of water. Into this solution are introduced 44.28 g of hydroxypropyl-cellulose and 44.28 g of cellulose, and if necessary homogenized.
A preparation for 1000 units, Part 2.
0.18 g of polyoxyethylene-polyoxypropylene polymer is dissolved in a mixture of 79.00 g of ethyl alcohol and 4.00 g of water. Into this solution are introduced 14~.91 g of h~droxypropyl-ceIlulose and 14.91 g of cellulose,~ and if necessary homogenized.
The suspensions thus :obtained are drawn on a suitable foil drawing apparatus having a two compartment s~ecial doctor (widths of the compartments: 1 =.54 mmi 2 = 18 mm) to form a sheet of 0..5 mm and then dried. By appropriate division into units measuring 18 x 18 mm, for example, by perforation, the foil can be divided over its width into three units containing active substance and one unit free from active substance. There may be produced in the web of foil any desired number of sections having a ratio of three units containing active substance to one unit containing no active .substance.
The composition of each unit:
Part 1 (containing active :substance) Part 2 (free from . ..... = . . active.. su~stance~
0.25 mg of d-norgestrel 0.05 mg of ethinyl-oestradiol 14.76 mg of hydroxypropyl-cellulose 14.91 mg 2014~76 mg of cellulose 14.91 mg 0.18 mg of polyoxyethylene-polyoxypropylene0.18 mg polymer 30.00 mg weight per unit 30.00 mg Area per unit: about 3 cm .
Appearance: white.
Example 18 Three phase preparation (two acti~e substance stage preparation) Part 1: 11 Units containing 0.05 mg of d-norgestrel diol.
Part 2: 10 Units containing 0.125 mg of d-n~rgestrel 0.050 mg of ethinyl-oestra-diol.
~67~
Part 3: 7 UnitS without active substance.preparation for 1100 units, Part 1:
0.055 g of d-noxgestre~ r 0.055 g of ethinyl-oestradiol and 0.198 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 86.900 g of ethyl alcohol and 4.400 g of water. Into this solution are introduced 16.346 g of hydroxypropyl-ceIlulose and 16.346 g of cellulsoe, and if necessary homogenized.
A preparation for 1000 units t Part 2.
0.125 g of d-norgestreI
0.050 g of ethinyl-oestradiol and 0.180 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 79.000 g of ethyl alcoho~ and 4.000 g of water. Into this solution are introduced 14.823 g of hydroxypropyl-ceIlulose and 14.822 g of cellulose, and if necessary homogenized.
A preparation for 700 units. Part 3:
0.189 g of polyoxyethylene-polyoxypropylene polymer is dissolved in a mixture of 82.950 g of ethyl alcohol and 4.200 g of water. Into this solution are introduced 15.656 g of hydroxypropyl-cellulose and 15.655 g of ceIlulose, and if necessary homogenized.
The suspensions thus obtained are drawn on a suitable foil drawing apparatus having a three compartment special doctor (width per compartment 18 mm~ to a sheet and dried. By appropriate division, or example, by perforationl there can be distributed over the width of the foil three units of 18 x 18 mm for Part 1, of 18 x 19.8 mm for Part 2 and of 18 x 28 for Part 3, having -~(~674~97 different contents of active substance. There can be separated from the foil web preparations having 11 units of Part 1, 10 units of Part 2 and 7 units of Part.3.
The composition per:unit:
Part 1 Part 2. Part.3. . In~redients O.OS0 mg 0.125 mg - d-norgestrel 0.050 m~ O.OS0 mg - ethinyl-oestradiol 0.180 mg 0.180 mg0.270 mg polyoxyethylene-polyoxypropylene polymer 1014.860 mg 14.823 mg23.366 mg hydroxypropyl-cellulose 1-4.860 mg 14.822 mg22.3-64 mg cellulose 30.000 mg 30.000 mg45.000 mg weight per unit about about about
The process of making the medicinal preparation in foil form in one operation (a continuous process) has the advantage that the active substance is homogeneously and uniformly distri-buted in the medicament carrier. By varying the concentration of the~active substance in the carrier, the thickness of the foil and the area of the foil the unit dose can be varied in a very simple manner.
Foils can also be made with a sheet in which different active substances and/or varying concentrations of active substance are incorpoxated side by side over the width of the web of foil.
Zo ` By means of a special doctor, which consists of two or more compartments, different solutions or suspensions can be drawn out without mixing to form a coherent sheet. The width and thickness of the sheet is separateIy adjustable for each compartment. If desired, zones (strips) having different active substances or different concentrations are made visible by different dyestuffs.
By drying the wet sheet there is obtained a foil, which by being divided in an appropriate manner, for example, by perforation, yields units containing different active substances and/or concentrations of active substance or units containing no active substance. Foils containing different active substances and/or different concentrations of active substance are required for making multi-phase preparations, for example, for making ~L~7~(37 contraceptive preparations~ The possibility o;E the spatial separation of active substances that are incompatible with one another i~ one foil unit improves the stability oE the individ-ual active substances. ~oils for intravaginal application may, for example, also be rolled round an ordinary commercial tampon.
The following examples illustrate the invention; with the exception of Examples 5 and 16, the preparations described in the examples are primarily suitable for oral administration.
Example 1 Preparation for 1000 units:
0.25 g of d-norgestrel, 0.05 g of ethinyl-oestradiol and 0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 95.00 g of ethyl alcohol while stirring, and into this is introduced a powdered mixture of 16.93 g of hydroxypropyl-ceIlulose and 16.93 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The composition of one unit:
0.25 mg of d-norgestrel 0.05 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.93 mg of hydroxypropyl-cellulose 16.93 mg of cellulose _. .
35.00 mg One unit corresponds to an area of about 3 cm2.
~ppearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
~0~7~
Exam~le 2 A preparation for 1000 units:
1.10 g of Cremophor EL ~ are dissol~ed in 152.00 g of water. In this solution are suspended 0.25 g of micronized d-norgestrel and 0.05 g of micronized ethinyl-oestradiol and if necessary homogenizea. Into the suspension are introduced 22.10 g of hydroxypropyl-ceIlulose and 16.50 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The com,position for one unit:
0.25 mg of d-norgestrel 0.05 mg of ethinyl-oestradiol 1.10 mg of Cremophor EL ~
22.10 mg of hydroxypropyl-cellulose 16.50 mg of cellulose 40.00 mg One unit corresponds to an area of about 3 cm .
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
'Ex'ample 3 A preparation for 1000 units:
0.03 ~ of d-norgestrel and 0.84 g of polyoxyl-40-stearate are dissolved, while stirring, in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 ~ of hydroxypropyl-ceIlulose and 17.20 g of cellulose.
~ ~7~q The suspension thus obtained .is drawn on a sultable ~oil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried~
The composition of one.unit:
0.03 mg o~ d-norgestrel 0.84 mg of polyoxyl-40-stearate 16.93 mg of hydroxypropyl-ceIlulose 17.20 mg of cell.ulose ..35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: ~hi.tel paper-like.
The dry foil has a thickness of about 170 ~m.
Example 4 A preparation for 1000 units:
1.10 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 152.00 g of demineralized water. In this solution is suspended 0.03 g of microized d-norgestrel, and if necessary homogenized. Into the suspension are introduced.
22..10 g of hydroxypropyl-cellulose and 16.77 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of.500 ~m, and is then dried.
The composition for one unit:
0O03 mg of d-norgestrel 1.10 mg of polyoxyethylene-polyoxypropylene polymer 22.10 mg of hydroxypropyl-cellulose 16.77 mg of cellulose -40.00 mg One unit corxesponds to an area of about 3 cm2.
Appearance of the.foil: white, paper-like.
The dry foil has a thickness of about 170 ~m, Exam_le.5 A preparation for 1000..units 0~025 g of fluocortolone trimethylacetate and 0.183 ~ of gylcerine are dissolved in .30.000 g of ethy.l alcohol. Into this solution are introduced 7.292 g of hydroxypropyl-cellulose~
The solution thus obtained is draw on a suitable foil drawing apparatus to a sheet having a thickness to.500 ~m, and is then dried.
The composition of one unit:
0.025 mg fluocortolone trimethylacetate 0..183 mg of glycerine - 7:.292 mg of hydroxypropyl-cellulose 7.500 mg One unit corresponds to an area of about 1 cm2.
Appearance of the foil: transparent.
The dry foil has a thickness of about 70 ~m.
The foil is suitable for topical use.
Examp:le 6 A preparation for 1000 units:
10.00 g of 7-chloro,2-methylamino-5-phenyl-3~-1,4-benzo-diazepine-4-oxide and 0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 g of hydroxypropyl-cellulose and 7.23 g of cellulose.
~6'74t~~
The suspension thus o~tained is drawn on a suitable foil dra~ing appaxatus to a sheet having a thickness o~ 500 ~m, and is then dried.
The composition of one unit:
10.00 mg of 7-chloro-2-meth~lamino-5-phenyl-3H-1,4-benzo-diazepine-~-oxide 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.93 mg of hydroxypropyl-cellulose 7.23 mg of cellulose 35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: yello~, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 7 A preparation for 1000 units:
1.00 g of norethisterone acetate, 0.03 g of ethinyl-oestradiol and 0.84 g of polyoxyethylene-polyoxypropylene polymer and dissolved in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 g of hydroxypropyl-cellulose and 16.20 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The composition for one unit:
1.00 mg of norethisterone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.93 mg of hydroxypropyl-cellulose 16.20 mg of cellulose 35.00 mg 4~
One unit corresponds to an area of about 3 cm2.
~ppearance of the ~oil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 8 A preparation for 1000units:
1.00 g of norethisterone acetate 0.03 g of ethinyl-oestradiol and 0.84 g of propylene glycol are dissolved in~.a mixture of 101.60 g of methylene chloride and 26.40 g of ethyl alcohol, Into this so}ution is introduced a powdered mixture of 8.47 g of hydroxypropyl-ceIlulose, 8.47 g of hydroxyethyl-ceIlulose and 16.19 g of cellulose.
The suspension thus obtained is drawn on a suitable fo'il drawing apparatus to a sheet having a thickness of 500 ~m, and is then dried.
The composition fox one unit:
1.00 mg of norethistèrone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of propylene glycol 8.47 mg of hydroxypropyl-cellulose 8.47 mg of hydroxyethyl-cellulose 16.19 mg of cellulose 35.00 ~g One unit corresponds to an area of about 3 cm2O
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 9 A preparation for 1000 units:
1.00 g of norethisterone aceta-te, 0.03 g of ethinyl-oestradiol and 7~
0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 101.60 g of methylene chloride and 25.40 ~ of ethyl alcohol. Into this solution is introduced a powdered mixture o~
16~93 g o:E hydroxyethyl-cellulose and 16.20 g of starch.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a~hickness of 500 ~m, and is then dried.
The composition for one unit:
1.00 mg o norethisterone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 15.93 mg of hydroxyethyl-cellulose and 16.20 mg of starch 35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Example 10 A preparation for 1000 units:
1.00 g of norethisterone acetate 0.03 g of ethinyl-oestradiol and 0.84 g of polyoxyl-40-stearate are dissol~ed in 95.00 g of ethyl alcohol. Into this solution is introduced a powdered mixture of 16.93 g of hydroxypropyl-cellulose 8.10 g of lactose and 8.10 g of maize starch.
The suspension thus obtained is drawn on a suitable ~ ~ t7~ ~ ~
foil drawing apparatus to a sheet ha~ing a thickness of 500 ~m, and is then dried.
The composition ~or one unit:
1.00 mg of norethisterone acetate 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyl-40-stearate 16.93 mg of hydroxypropyl-cellulose 8.10 mg of lactose 8.10 mg of maize starch 35.00 mg One unit corresponds to an area of about 3 cm2.
Appearance of the foil: ~hite, paper-like.
The dry foil has a thickness of about 170 ~m.
Example ll A preparation for 1000 units:
1.00 g of norethisterone~(l7~-ethinyl-19-nor-testosterone) 0.03 g of ethinyl-oestradiol and 0.22 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 84.75 g of ethyl alcohol and 4.00 g of water. Into this solution is introduced a powdered mixture of 16.00 g of hydroxypropyl-cellulose and 16.00 g of cellulose.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 600 ~m and then dried.
The composition for one unit:
1.00 mg of noxethisterone ~17~-ethinyl-l9-nor-testosterone) 0.03 mg o~ ethinyl-oestradiol 0.22 mg of polyoxyethylene-polyoxypropylene polymer 16.00 mg of hydroxypropyl-cellulose ~7~
16.00 mg of cellulose .
33.25 mg One unit corresponds to an area of about 3 çm2.
Appear~nce o~ the ~oil: white, paper~like.
The dry foil has a thickness of approx. 230 ~m.
Example 12 A preparation for 1000 uni*s:
4.0 g of glisoxepide.* in micronised form are suspended in 0..9 g of polyoxyl-40-stearate dissolved in .152.0 g of water, and:if necessary homogenized. Into the suspension are introduced 15.0 g of hydxoxyethyl-ceIlulose and 15.1 g of calcium carbonate.
The suspension thus obtained is drawn on a suitable foil drawing appara*us to a sheet having a thickness of.500 ~m and dried.
The composition for one unit:
4.00 mg of glisoxepide.*
0090 mg of polyoxyl-40 stearate 15.00 mg of hydroxyethyl-cellulose 15.10 mg of calc.ium carbonate -.35.00 mg One unit corresponds.to an area of about 3 cm2.
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
4-{~-[~-(5-methyl-isoxazol-3-carboxamido~-ethyl~-benzolsulphonyl}-l,l-hexamethylene-semicarbazide.
Example 13 A preparation for lOOO.units:
0.030 g of d norgestreI are dissolved in 40.000 g of methylene chloride and 55.000 g of ethanol. Into this solution are introduced 0.840 g of silicone oil 6.930 g of methyl-cellulo:se and 10.000 g of poly-N.-vinyl-pyrrolidone and 17.200 g of starch~,and i~ necessary homoyenlzed.
The suspension thus obta:ined is drawn on a :suitable foil drawing apparatus to a sheet having a t:hickness of;500 ~m and dried.
The composition of one~.unit:
Ø.030 mg of d-norgestrel 0.840 mg of silicone oil 6.930 mg of methyl-cellulose 10.000 mg of poly-N-~inyl-pyrrolidone 17:.200 mg of starch .35.000 mg One unit corresponds to an area of about.3 cm .
Appearance of the foil: white, paper-like.
The dry foil has a thickness of about 170 ~m.
Ex'ampl'e''14 A preparation for 1000. units:
0.84 g of polyoxyethylene-polyoxypropylene polymer are dissolved in 95.00 g of ethyl alcohol while stirring, and into this solution is introduced a powdered mixture of 17.08 g of hydroxypropyl-ceIlulose and 17.08 g of cellulose.
The suspension thus obtained is drawn on a suitahle foil dra~ing app~ratus to a sheet having a thickness of 500 ~m and then dried~
~)t;i7~0P7 The compositi.on ~or one unit:
0.84 mg of polyoxyethylene-polyoxypropylene polymer 17.08 mg of hydroxypropyI-ceIlulsoe 17.08 mg of cellulose ..35.00 mg Exampl:e :15`
A preparati.on for 1000 units:
0.04 g of saccharin 0.04 g of cream essence and 0.40 g of polyoxyethylene-polyoxypropyl.ene:polymer are dissolved in a mixture of 79.00 g of ethyl alcohol and 4.00 g of water. Into this solution are introduced .30:.00 g of iron (II? .umarate, .15.00 g of hydroxypropyl-cellulose, 5..52 g of cocoa and 4:.00 g of ceI.lulose, and if necessaxy homogenized.
The suspension thus obtained is drawn on a suitable foil drawing apparatus to a sheet having a thickness of 0.5 mm, and then dried.
The composition for one unit:
30.00 mg of iron (II) :fumarate 15.00 mg of hydroxypropyl-cellulose 4.00 mg of cellulose 0.40 mg of polyoxyethylene-polyoxypropylene polymer 5..52 mg of co.coa 0.04 mg of saccharin 0.04 mg of cream ess~ence 55.00 mg. Weight per unit.
One unit corresponds to an ar~a of about 3 cm2.
Appearance o the foil: pale red-brown.
~;7~
Example 16 Foils for intravaginal application;
The foil is prepared in accordance with Example ll.
The co~position of one unit 100.0 mg of S-morpholinomethyl-3-(5-nitro-1-methyl-2-imidazolyl)-methyleneamino-2-oxazoli-done.HCl 8.4 mg of Cremopho~ EL ~
169.2 mg of methylhydroxypropyl-cellulose 72.4 mg of cellulose 350.0 mg. Weight of one unit.
One unit corresponds to an area of about 8 x 4 cm.
Appearance of the foil: pale yellow.
The $oil (1 unit~ is either rolled round an ordinary commercial tampon or is itself rolled to form a naErow tube.
EXample 17 A two phase preparation Part 1: 21 units containing active substance.
Part 2: 7 units without active substance.
A preparation for 3000 units. Part 1.
0.75 g of d-norgestrel 0.15 g of ethinyl-oestradiol and 0.54 g of polyoxethylene-polyoxypropylene polymer are dissol~ed in a mixture of 237.00 g of ethyl alcohol and 12.00 g of water. Into this solution are introduced 44.28 g of hydroxypropyl-cellulose and 44.28 g of cellulose, and if necessary homogenized.
A preparation for 1000 units, Part 2.
0.18 g of polyoxyethylene-polyoxypropylene polymer is dissolved in a mixture of 79.00 g of ethyl alcohol and 4.00 g of water. Into this solution are introduced 14~.91 g of h~droxypropyl-ceIlulose and 14.91 g of cellulose,~ and if necessary homogenized.
The suspensions thus :obtained are drawn on a suitable foil drawing apparatus having a two compartment s~ecial doctor (widths of the compartments: 1 =.54 mmi 2 = 18 mm) to form a sheet of 0..5 mm and then dried. By appropriate division into units measuring 18 x 18 mm, for example, by perforation, the foil can be divided over its width into three units containing active substance and one unit free from active substance. There may be produced in the web of foil any desired number of sections having a ratio of three units containing active substance to one unit containing no active .substance.
The composition of each unit:
Part 1 (containing active :substance) Part 2 (free from . ..... = . . active.. su~stance~
0.25 mg of d-norgestrel 0.05 mg of ethinyl-oestradiol 14.76 mg of hydroxypropyl-cellulose 14.91 mg 2014~76 mg of cellulose 14.91 mg 0.18 mg of polyoxyethylene-polyoxypropylene0.18 mg polymer 30.00 mg weight per unit 30.00 mg Area per unit: about 3 cm .
Appearance: white.
Example 18 Three phase preparation (two acti~e substance stage preparation) Part 1: 11 Units containing 0.05 mg of d-norgestrel diol.
Part 2: 10 Units containing 0.125 mg of d-n~rgestrel 0.050 mg of ethinyl-oestra-diol.
~67~
Part 3: 7 UnitS without active substance.preparation for 1100 units, Part 1:
0.055 g of d-noxgestre~ r 0.055 g of ethinyl-oestradiol and 0.198 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 86.900 g of ethyl alcohol and 4.400 g of water. Into this solution are introduced 16.346 g of hydroxypropyl-ceIlulose and 16.346 g of cellulsoe, and if necessary homogenized.
A preparation for 1000 units t Part 2.
0.125 g of d-norgestreI
0.050 g of ethinyl-oestradiol and 0.180 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 79.000 g of ethyl alcoho~ and 4.000 g of water. Into this solution are introduced 14.823 g of hydroxypropyl-ceIlulose and 14.822 g of cellulose, and if necessary homogenized.
A preparation for 700 units. Part 3:
0.189 g of polyoxyethylene-polyoxypropylene polymer is dissolved in a mixture of 82.950 g of ethyl alcohol and 4.200 g of water. Into this solution are introduced 15.656 g of hydroxypropyl-cellulose and 15.655 g of ceIlulose, and if necessary homogenized.
The suspensions thus obtained are drawn on a suitable foil drawing apparatus having a three compartment special doctor (width per compartment 18 mm~ to a sheet and dried. By appropriate division, or example, by perforationl there can be distributed over the width of the foil three units of 18 x 18 mm for Part 1, of 18 x 19.8 mm for Part 2 and of 18 x 28 for Part 3, having -~(~674~97 different contents of active substance. There can be separated from the foil web preparations having 11 units of Part 1, 10 units of Part 2 and 7 units of Part.3.
The composition per:unit:
Part 1 Part 2. Part.3. . In~redients O.OS0 mg 0.125 mg - d-norgestrel 0.050 m~ O.OS0 mg - ethinyl-oestradiol 0.180 mg 0.180 mg0.270 mg polyoxyethylene-polyoxypropylene polymer 1014.860 mg 14.823 mg23.366 mg hydroxypropyl-cellulose 1-4.860 mg 14.822 mg22.3-64 mg cellulose 30.000 mg 30.000 mg45.000 mg weight per unit about about about
3 cm2 3'5 cm25 cm area per unit ~hite ~hite white appearance . .
:
Example 19 Three phase preparation:
Part 1: 11 Units containing 0.05 mg of d-norgestrel 0..05 mg of ethinyl-oestradiol Part 2: 10 Units containing 0.125 mg of d-norgestrel 0.050 ~g of ethinyl-oestradiol Part 3: 7 Units containing50.00 mg of iron (II) :fumarate.
A preparation for 1100 units. Part 1:
0.066 g of food colour yeIlow No. 2 (tartrazine; E 102) is dissolved in
:
Example 19 Three phase preparation:
Part 1: 11 Units containing 0.05 mg of d-norgestrel 0..05 mg of ethinyl-oestradiol Part 2: 10 Units containing 0.125 mg of d-norgestrel 0.050 ~g of ethinyl-oestradiol Part 3: 7 Units containing50.00 mg of iron (II) :fumarate.
A preparation for 1100 units. Part 1:
0.066 g of food colour yeIlow No. 2 (tartrazine; E 102) is dissolved in
4.400 g of water, and then introduced into 86.900 g of ethyl alcohol. In this solution axe dissolved 0.055 g of d-norgestrel 0.055 g of ethinyl-oestradiol and 0.198 g of polyoxyethylene-polyoxypropylene polymer.
Into this solution are in-troduced 16.313 g of hydroxypropyl.-cellulose and 16..313 g of cellulose, and if necessary homogenized.
preparation for lOOO.units. Part 2:
0.065 g of food..colour orange No. 2 (Sunset ~ellow;
E 110~ is disso:lved in 4.000 g o~ water, and then introduced into 79.000 g of ethyl alcohol. In this solution are dissolved 0.125 g of d-norgestr~el 0..050 g of ethinyl-oestradiol and 0.18 g of polyoxyethylene-polyoxypropylene polymer.
Into this solution are:introduced 14.790 ~ of hydroxypropyl-.cellulose and 14.790 g of cellulose, and if necessaxy homo~enized.
A preparation for 700 units. Part.3:
0.042 g of saccharin 0.042 g of cream essence and 0.406 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 55.300 g of ethyl alcohol and 2.800 g of water. Into this solution are introduced .35.000 g of iron (II) .fumarate 17.500 g of hydroxypropyl-.cellulose
Into this solution are in-troduced 16.313 g of hydroxypropyl.-cellulose and 16..313 g of cellulose, and if necessary homogenized.
preparation for lOOO.units. Part 2:
0.065 g of food..colour orange No. 2 (Sunset ~ellow;
E 110~ is disso:lved in 4.000 g o~ water, and then introduced into 79.000 g of ethyl alcohol. In this solution are dissolved 0.125 g of d-norgestr~el 0..050 g of ethinyl-oestradiol and 0.18 g of polyoxyethylene-polyoxypropylene polymer.
Into this solution are:introduced 14.790 ~ of hydroxypropyl-.cellulose and 14.790 g of cellulose, and if necessaxy homo~enized.
A preparation for 700 units. Part.3:
0.042 g of saccharin 0.042 g of cream essence and 0.406 g of polyoxyethylene-polyoxypropylene polymer are dissolved in a mixture of 55.300 g of ethyl alcohol and 2.800 g of water. Into this solution are introduced .35.000 g of iron (II) .fumarate 17.500 g of hydroxypropyl-.cellulose
5.950 g of cocoa and 4.060 g of cellulose, and if necessary ho~ogenized.
The suspensions so prepared are drawn on a suitable foil drawing apparatus having a three compartment special doctor (width per compartment 18 mm) to a sheet and dried. By appropri-ate division, for example, by perforation, there can be distribu-ted over the width of the foil three units of 18 x 18 mm for Part 1, of 18 x 19.8 mm for Part 2 and of 18 x 28 mm for Part 3, 7~
having different contents of acti.ve substance. r~here can be separated from the ~oil web preparations having ll..unit o~
Part 1, 10 units of Part.2 and 7 units oE ~art 3.
The composition per.unit:
Part 1 P~rt 2Part 3 In~redients 0.050 mg 0.125 mg - 'd-norgestrel O... OS0 mg 0.050 mg - ethinyl-oestradiol - - 50.000 mg iron ~II) fumarate 0~180 mg a .180 mg 0.580 mg polyoxyethylene-polyoxypropylene polymer 0.060 mg - - food colour yellow No. 2 - 0.065 mg - food colour orange No. 2 14.830 mg 14.790 mg25'.000 mg hydroxypropyl-cellulose 14.830 mg 14.790 mg5.800 mg cellulose - - 8.500 mg cocoa - - 0.060 mg saccharin .. . - - . .. 0.. 06Ømg cream essence .
20 30.000 mg 30.000 mg 90.000 mg weight per unit about about about 3 cm2 3.5 cm2 5 cm2 area per unit yel.low . orange br.own . . .... a.ppe:a.rance .
Exa~ple 20 Preparation for 1000 units 0.15 g of d-norgestreI
0.03 g of ethinyl-oestradiol and 0.84 g of polyoxethylene-polyoxypropylene polymer are dissol~ed in 95.00 g of ethyl alcohol while stirring and a powdered mixture o~
16.99 g of hydroxypropyl-cellulose and 16.99 g of cellulose is introduced into this solution.
The suspension obt~ined is drawn out on a suitable foil drawing apparatus to ~ very thin foil having a thi.ckness of 500 ~m, and is then dried.
The composition of one unit:
0.15 mg of d-norgestrel 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.99 mg of hydroxypropyl-cellulose 16.99 mg of cellulose 35.00 One unit corresponds to.an area of approxO 3 cm2 Appearance of the: foil: white, paper-like.
The dry foil has a thickness of approx. 170 ~m.
The suspensions so prepared are drawn on a suitable foil drawing apparatus having a three compartment special doctor (width per compartment 18 mm) to a sheet and dried. By appropri-ate division, for example, by perforation, there can be distribu-ted over the width of the foil three units of 18 x 18 mm for Part 1, of 18 x 19.8 mm for Part 2 and of 18 x 28 mm for Part 3, 7~
having different contents of acti.ve substance. r~here can be separated from the ~oil web preparations having ll..unit o~
Part 1, 10 units of Part.2 and 7 units oE ~art 3.
The composition per.unit:
Part 1 P~rt 2Part 3 In~redients 0.050 mg 0.125 mg - 'd-norgestrel O... OS0 mg 0.050 mg - ethinyl-oestradiol - - 50.000 mg iron ~II) fumarate 0~180 mg a .180 mg 0.580 mg polyoxyethylene-polyoxypropylene polymer 0.060 mg - - food colour yellow No. 2 - 0.065 mg - food colour orange No. 2 14.830 mg 14.790 mg25'.000 mg hydroxypropyl-cellulose 14.830 mg 14.790 mg5.800 mg cellulose - - 8.500 mg cocoa - - 0.060 mg saccharin .. . - - . .. 0.. 06Ømg cream essence .
20 30.000 mg 30.000 mg 90.000 mg weight per unit about about about 3 cm2 3.5 cm2 5 cm2 area per unit yel.low . orange br.own . . .... a.ppe:a.rance .
Exa~ple 20 Preparation for 1000 units 0.15 g of d-norgestreI
0.03 g of ethinyl-oestradiol and 0.84 g of polyoxethylene-polyoxypropylene polymer are dissol~ed in 95.00 g of ethyl alcohol while stirring and a powdered mixture o~
16.99 g of hydroxypropyl-cellulose and 16.99 g of cellulose is introduced into this solution.
The suspension obt~ined is drawn out on a suitable foil drawing apparatus to ~ very thin foil having a thi.ckness of 500 ~m, and is then dried.
The composition of one unit:
0.15 mg of d-norgestrel 0.03 mg of ethinyl-oestradiol 0.84 mg of polyoxyethylene-polyoxypropylene polymer 16.99 mg of hydroxypropyl-cellulose 16.99 mg of cellulose 35.00 One unit corresponds to.an area of approxO 3 cm2 Appearance of the: foil: white, paper-like.
The dry foil has a thickness of approx. 170 ~m.
Claims (14)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. In a pharmaceutical composition in unit dosage form for enteral or topical administration and comprising a safe and effective amount of a pharmaceutically active medicament compound and a flexible, water soluble film carrier therefore, the improve-ment wherein the medicament is dissolved or uniformly suspended, together with about 0.01 - 2% by weight of a pharmaceutically acceptable release agent in a film carrier consisting essentially of a non-ionic, water soluble methyl ether or hydroxyalkyl ether of cellulose and the pharmaceutical composition is in the form of a tissue-like sheet, having a uniform dry film thickness of about 0.05 - 1 mm, drawn from a solution of the film carrier containing 0.01 - 2% by weight of a pharmaceutically acceptable release agent, 0 - 30% by weight of a filler and up to 60% by weight of the film carrier of the medicament.
2. A composition according to claim 1, wherein the film carrier is hydroxypropyl-cellulose, hydroxyethyl-cellulose, methyl-hydroxypropylcellulose and mixtures thereof.
3. A composition according to claim 1, wherein the medicament is an estrogen, gestagen or admixture thereof.
4. A composition according to claim 1, wherein the release agent is a polyoxethylene-polyoxypropylene copolymer(s), a polyoxylstearate or an alkyl- or alkanoyl-substituted poly-addition product of ethylene oxide.
5. A composition according to claim 1 wherein the medi-cament or concentration thereof differs in areas thereof defined by strips adjacent to one another along the width of the sheet.
6. A composition according to claim 5, wherein the strips are identified by different dyestuffs.
7. A composition according to claim 1, wherein the sheet is perforated to provide a plurality of single-unit dosages.
8. A composition according to claim 1, wherein the sheet is a transparent and smooth film.
9. A composition according to claim 1 containing a water-insoluble filler uniformly suspended in the film carrier and the film is paper-like.
10. A composition according to claim 9, wherein the filler is cellulose.
11. A composition according to claim 1, wherein the film carrier is methyl cellulose.
12. A composition according to claim 1, wherein the sheet has a thickness of 0.07 - 0.3 mm.
13. A composition according to claim 1, wherein the film carrier is hydroxypropyl-cellulose, hydroxyethyl-cellulose, methylhydroxypropyl-cellulose or a mixture thereof; the medica-ment is an estrogen, gestagen or admixture thereof; the release agent is a polyoxyethylene-polyoxypropylene copolymer, a polyoxyl stearate or an alkyl- or alkanoyl-substituted poly- addition product of ethylene oxide; and the sheet has a thickness of 0.07 -0.3 mm.
14. A process for the production of a pharmaceutical composition in unit dosage form for enteral or topical adminis-tration and comprising a safe and effective amount of a pharma-ceutically active medicament compound and a flexible, water sol-uble film carrier therefore, which process comprises: (a) draw-ing into a sheet having a uniform layer thickness of about 0.1 -2 mm and a dry thickness of about 0.05 - 1 mm, a homogeneous solu-tion or suspension consisting essentially of (1) up to 60% by weight, based on the film carrier, of the medicament, (2) 0 - 30 by weight of a pharmaceutically acceptable filler, (3) a film-forming amount of a water-soluble film-forming polymer, and (4) as solvent or suspending medium, one or both of water and an organic volatile solvent system comprising an organic polar sol-vent miscible in water; and (b) drying the thus-formed sheet to remove the solvent or suspending medium therefrom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2432925A DE2432925C3 (en) | 1974-07-05 | 1974-07-05 | Film-shaped medicinal products |
DE19742449865 DE2449865B2 (en) | 1974-10-17 | 1974-10-17 | Film-shaped medicinal product |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1067407A true CA1067407A (en) | 1979-12-04 |
Family
ID=25767384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA230,802A Expired CA1067407A (en) | 1974-07-05 | 1975-07-04 | Pharmaceutical preparation in the form of a foil having an active substance incorporated therein |
Country Status (17)
Country | Link |
---|---|
JP (1) | JPS6028810B2 (en) |
CA (1) | CA1067407A (en) |
CH (1) | CH625704A5 (en) |
DD (1) | DD122196A5 (en) |
DK (1) | DK143221C (en) |
EG (1) | EG11756A (en) |
FI (1) | FI60354C (en) |
FR (1) | FR2276811A1 (en) |
GB (1) | GB1510999A (en) |
IE (1) | IE42604B1 (en) |
IL (1) | IL47573A (en) |
IN (1) | IN142428B (en) |
NL (1) | NL186294C (en) |
NO (1) | NO752416L (en) |
PH (1) | PH18973A (en) |
RO (1) | RO68836A (en) |
SE (1) | SE413285B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289386B2 (en) | 2009-01-29 | 2016-03-22 | Nitto Denko Corporation | Oral film-form base and oral film-form preparation |
US9724309B2 (en) | 2010-03-30 | 2017-08-08 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
US10092505B2 (en) | 2012-01-11 | 2018-10-09 | Nitto Denko Corporation | Oral film-form base and preparation |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU514195B2 (en) | 1975-12-15 | 1981-01-29 | F. Hoffmann-La Roche & Co. | Dosage form |
US4332789A (en) | 1975-12-15 | 1982-06-01 | Hoffmann-La Roche Inc. | Pharmaceutical unit dosage forms |
GB1601923A (en) * | 1977-06-09 | 1981-11-04 | Beecham Group Ltd | Sustained release compositions |
IL59063A (en) * | 1979-01-11 | 1983-12-30 | Key Pharma | Polymeric diffusion matrix for release of pharmaceutical dosage |
EP0063657A1 (en) * | 1981-04-29 | 1982-11-03 | Merck & Co. Inc. | Topical application of interferon inducers |
JPS59222406A (en) * | 1983-06-01 | 1984-12-14 | Teijin Ltd | Pharmaceutical preparation for remedying periodontosis and its preparation |
JPS6086576U (en) * | 1983-11-15 | 1985-06-14 | 株式会社豊田自動織機製作所 | Weft guide device in weft storage device of fluid jet loom |
JPS61280423A (en) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
DE3601923A1 (en) * | 1986-01-23 | 1987-07-30 | Behringwerke Ag | NASAL APPLICABLE MEDICINE, METHOD FOR THE PRODUCTION AND USE THEREOF |
SE8602666D0 (en) * | 1986-06-16 | 1986-06-16 | Leo Ab | INTRAVAGINAL DEVICES |
DE3630603A1 (en) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
DE4018247A1 (en) * | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | MANUFACTURING METHOD FOR QUICK-DISINFITTING FILM-SHAPED PHARMACEUTICAL FORMS |
DE19549506C2 (en) * | 1995-03-07 | 1998-07-30 | Richard Prof Dr Sueverkruep | Pharmaceutical or diagnostic dosage form, esp. for ophthalmic use |
DE19646392A1 (en) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
JP3460538B2 (en) * | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | Fast dissolving film preparation |
DE19745208A1 (en) * | 1997-10-13 | 1999-04-15 | Labtec Gmbh | Pharmaceutical film that dissolves in mouth |
DE19856101A1 (en) * | 1998-12-04 | 2000-06-08 | Labtec Gmbh | Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio |
CA2373983C (en) | 1999-07-02 | 2007-11-13 | The Procter & Gamble Company | Systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
DE10207394B4 (en) * | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Taste-masked oblate medicinal preparation |
JP2004043450A (en) * | 2002-05-16 | 2004-02-12 | Kyukyu Yakuhin Kogyo Kk | Quickly soluble filmy preparation |
WO2003097103A1 (en) * | 2002-05-16 | 2003-11-27 | Kyukyu Pharmaceutical Co.,Ltd. | Quickly soluble film preparations |
US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
ATE553746T1 (en) * | 2003-01-30 | 2012-05-15 | Monosolrx Llc | METHOD FOR PRODUCING A THIN FILM CONTAINING THERMOLABILITY ACTIVE INGREDIENTS |
DE10354894A1 (en) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Oral formulations of deoxypeganine and their applications |
DE102005003387A1 (en) * | 2004-09-01 | 2006-03-02 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios |
CA2664097A1 (en) | 2006-09-20 | 2008-03-27 | Monosol Rx, Llc | Edible water-soluble film containing a foam reducing flavoring agent |
US20080260836A1 (en) * | 2007-04-18 | 2008-10-23 | Thomas James Boyd | Films Comprising a Plurality of Polymers |
JP2010158173A (en) * | 2009-01-06 | 2010-07-22 | Lintec Corp | Edible film, edible film composition, and method for producing edible film laminated body |
JP5379499B2 (en) * | 2009-01-29 | 2013-12-25 | リンテック株式会社 | Swallow package and edible film assembly |
JP5497358B2 (en) * | 2009-07-28 | 2014-05-21 | リンテック株式会社 | Edible laminated film and method for producing the same |
JP5588688B2 (en) * | 2010-01-28 | 2014-09-10 | 日東電工株式会社 | Film-form preparation |
JP5466028B2 (en) * | 2010-02-03 | 2014-04-09 | リンテック株式会社 | Edible sheet and food holding sheet |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
FR2968004B1 (en) * | 2010-11-29 | 2013-06-28 | Sojasun Technologies | BIODEGRADABLE NATURAL FILMS BASED ON CO-PRODUCTS FROM INDUSTRIAL PROCESSES FOR SEED TREATMENT. |
US10285915B2 (en) | 2012-10-17 | 2019-05-14 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
US20180104183A1 (en) * | 2015-04-07 | 2018-04-19 | Nipro Corporation | Oral film preparation |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
CN109310646A (en) | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Epinephrine composition for enhanced delivery |
AU2018290925A1 (en) * | 2017-06-30 | 2020-01-16 | Allergan, Inc. | Dissolving film for delivery of a Clostridial derivative |
-
1975
- 1975-05-19 IN IN993/CAL/1975A patent/IN142428B/en unknown
- 1975-06-17 FI FI751801A patent/FI60354C/en not_active IP Right Cessation
- 1975-06-24 JP JP50078601A patent/JPS6028810B2/en not_active Expired
- 1975-06-26 IL IL47573A patent/IL47573A/en unknown
- 1975-06-30 RO RO7582701A patent/RO68836A/en unknown
- 1975-06-30 DK DK295075A patent/DK143221C/en not_active IP Right Cessation
- 1975-06-30 NL NLAANVRAGE7507785,A patent/NL186294C/en not_active IP Right Cessation
- 1975-07-02 EG EG382A patent/EG11756A/en active
- 1975-07-02 PH PH17340A patent/PH18973A/en unknown
- 1975-07-03 DD DD187079A patent/DD122196A5/xx unknown
- 1975-07-03 IE IE1474/75A patent/IE42604B1/en unknown
- 1975-07-03 SE SE7507659-6A patent/SE413285B/en not_active IP Right Cessation
- 1975-07-03 NO NO752416A patent/NO752416L/no unknown
- 1975-07-03 CH CH870075A patent/CH625704A5/en not_active IP Right Cessation
- 1975-07-04 FR FR7521022A patent/FR2276811A1/en active Granted
- 1975-07-04 CA CA230,802A patent/CA1067407A/en not_active Expired
- 1975-07-04 GB GB28252/75A patent/GB1510999A/en not_active Expired
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289386B2 (en) | 2009-01-29 | 2016-03-22 | Nitto Denko Corporation | Oral film-form base and oral film-form preparation |
US9724309B2 (en) | 2010-03-30 | 2017-08-08 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
US10092505B2 (en) | 2012-01-11 | 2018-10-09 | Nitto Denko Corporation | Oral film-form base and preparation |
Also Published As
Publication number | Publication date |
---|---|
DD122196A5 (en) | 1976-09-20 |
JPS5129218A (en) | 1976-03-12 |
DK143221C (en) | 1981-11-30 |
IE42604B1 (en) | 1980-09-10 |
GB1510999A (en) | 1978-05-17 |
AU8252775A (en) | 1977-01-06 |
SE413285B (en) | 1980-05-19 |
FR2276811A1 (en) | 1976-01-30 |
FI751801A7 (en) | 1976-01-06 |
SE7507659L (en) | 1976-01-07 |
IN142428B (en) | 1977-07-09 |
RO68836A (en) | 1980-07-15 |
FI60354B (en) | 1981-09-30 |
NL7507785A (en) | 1976-01-07 |
DK295075A (en) | 1976-01-06 |
NL186294C (en) | 1990-11-01 |
PH18973A (en) | 1985-11-26 |
IL47573A0 (en) | 1975-08-31 |
IL47573A (en) | 1978-10-31 |
CH625704A5 (en) | 1981-10-15 |
NL186294B (en) | 1990-06-01 |
JPS6028810B2 (en) | 1985-07-06 |
NO752416L (en) | 1976-01-06 |
FI60354C (en) | 1982-01-11 |
EG11756A (en) | 1977-11-30 |
DK143221B (en) | 1981-07-27 |
FR2276811B1 (en) | 1980-04-11 |
IE42604L (en) | 1976-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1067407A (en) | Pharmaceutical preparation in the form of a foil having an active substance incorporated therein | |
US4136162A (en) | Medicament carriers in the form of film having active substance incorporated therein | |
US4136145A (en) | Medicament carriers in the form of film having active substance incorporated therein | |
DE2432925C3 (en) | Film-shaped medicinal products | |
US4138013A (en) | Enteric capsules | |
US4317447A (en) | Drug delivery system | |
US6372246B1 (en) | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals | |
AU2001283909B2 (en) | Solution-, Dispersion-or emulsion-producing film dermatics | |
AP679A (en) | Oral 2-methyl-thieno-benzodiazepine formulation. | |
DE2449865A1 (en) | Medicaments in form of foils - prepd. by incorporating a drug in a soluble foil-forming material | |
CA2329556A1 (en) | Method of preparing a watersoluble film | |
JP2716231B2 (en) | Occluder for administration of physiologically active substances | |
FI84783C (en) | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICALS AND PREPARATIONS. | |
US4344968A (en) | Pharmaceutical vehicle | |
KR0124791B1 (en) | Film coated tablet | |
NZ192532A (en) | Polymeric diffusion matrix and a transdermal drug delivery device | |
PL190376B1 (en) | Water-soluble instantly wettable film or layer for use in oral administration | |
JPS62267221A (en) | Novel medicine | |
CZ321594A3 (en) | Pharmaceutical preparation for inhibiting changes of skin and vagina | |
US3197369A (en) | Coated gelatin capsules | |
US4421738A (en) | Sugar-coated tablet containing fat-soluble pharmaceutical material | |
CN103340822B (en) | Vaginal expansion suppository containing econazole or econazole salt, and preparing method and detection methods thereof | |
JPH04505328A (en) | osmotic dosage form | |
MC1315A1 (en) | IMIDAZOLE DERIVATIVES AND THEIR SYNTHESIS AND PREPARATION OF MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES | |
US3383283A (en) | Medicinal pellets coated with overlapping porous fatty acid leaflet layers |